Phase IV Study of the Outpatient Treatment of Gram Positive Wound Infections in the Diabetic Foot: A Pharmaco-Economic Comparison of Daptomycin vs Vancomycin Based Regimens
试验速览
- 阶段
- 4 期
- 状态
- 终止
- 发起方
- 入组人数
- 6
- 试验地点
- 2
- 主要终点
- Pharmaco-economic
研究概览
简要总结
The purpose of the study is to evaluate the overall burden to the participant (economic, quality of life, patients satisfaction and freedom from side effects) when treating Gram positive infections of the foot in diabetic adults with daptomycin versus vancomycin.
详细描述
- to compare the overall economic burden of therapy of a daptomycin vs. a vancomycin based antibiotic regimen for diabetic foot infections in the outpatient setting
- to compare Quality of Life and patient satisfaction among recipients of a daptomycin vs. a vancomycin based regimen
- to compare the safety and tolerance (adverse experiences) of daptomycin vs. vancomycin based regimens
- to compare the efficacy (complete resolution of infection) of daptomycin vs. vancomycin based regimens
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age 18-80 who are able to give informed consent and, who are likely to be able to participate through the full 28 day of the study.
- •Previously diagnosed diabetes mellitus, requiring the use of insulin and/or oral hypoglycemic agents for glycemic control.
- •The presence of an infection of one or both feet (defined as being distal to the superior-most point of the lateral malleolus), with some drainage, abscess or fluid collection that can be cultured, yet which as not been treated for greater than 24 hours with prior oral antibiotic therapy within the last 48 hours, wand which does not include either a quinolone or linezolid. The foot lesion, in the opinion of the initial treating physician, is severe enough (either because of the lesion or because of the subject's diabetic control, vasculopathy, etc) to require intravenous antibiotics.
- •A culture of the wound, either at the time of screening or within the 72 hours prior to screening, that yields a Gram positive organism that is shown to be sensitive (or is likely to be sensitive) to both vancomycin and daptomycin. This will include Staphylococcus aureus, (including MSSA and MRSA, but excluding VRSA), Enterococcus faecalis and enterococcus faecium (excluding VRE), streptococci, including Groups A and B, as well as other beta-hemolytic streptococci, viridans streptococci, and Group D. A culture of coagulase negative staphylococci as the only Gram positive isolate will not be considered for participation. Cultures may be obtained as swab or fluid submitted for culture.
- •Able to read and write in English with a proficiency suitable for completing the pharmaco-economic and quality of life questionnaires and diaries.
排除标准
- •No Gram positive bacteria identified in the infected foot, infection with a Gram positive organism that is resistant to one of the two study drugs, or infection with coagulase negative staphylococci as the only Gram positive organism isolated.
- •Known hypersensitivity to either of the two proposed study agents, or to ciprofloxacin, if a second anti-microbial agent is necessary.
- •Renal dysfunction, such that the study subject requires dialysis.
- •The presence of active osteomyelitis in the foot.
- •The presence of concomitant infections that would require antibiotic therapy in addition to that being prescribed for the foot infection.
- •The presence of pneumonitis requiring antimicrobial therapy, regardless of the suspected etiologic organism.
- •A history of drug induced ototoxicity (either auditory or vestibular).
- •A history of previous or current vascular catheter-associated phlebitis.
- •Pregnancy or breastfeeding.
- •Alcohol or drug use which, in the opinion of the investigator, is likely to interfere with the conduct of the study.
研究组 & 干预措施
daptomycin
Dosed at 6mg/kg body weight intravenously every 24 hours with a reduction to 6mg/kg every other day if creatinine clearance (CrCl)is <30ml/min.
干预措施: Cubicin (Drug)
vancomycin
Dosed at 15mg/kg intravenously every 12 hours with adjustments for renal function.
干预措施: Vancomycin (Drug)
结局指标
主要结局
Pharmaco-economic
时间窗: 28 days
Based upon 2 economic parameters associated with the treatment of the infection (provider charges and out-of-pocket costs) from screening until Day 28. Provider charges, as documented in invoices submitted to the pt's. insurance company, will be collected for all activities and services provided by the physician's office,home infusion company, laboratory, etc. during the study period. Out of pocket costs will be captured in a pt. diary and will include any health related costs that are borne by the pt. during the study period. Costs and charges will be analyzed and reported separately.
次要结局
- Quality of Life/patient satisfaction(28 days)
研究者
Donald Poretz
Research Director
Clinical Alliance for Research & Education - Infectious Diseases, LLC.